Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 1 3Phase 4 2Phase 2 2Phase 3 1Phase 2/3 1

Status

Completed 77Terminated 18Active not recruiting 11Recruiting 7Not yet recruiting 3Withdrawn 2Unknown 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Conditions

Tuberous Sclerosis 1Lymphangioleiomyomatosis 1Kaposiform Hemangioendothelioma 1Hemangioendothelioma 1

Interventions

Cisplatin 267Oxaliplatin 194Carboplatin 189Capecitabine 183Docetaxel 176apatinib 164Paclitaxel 158Bevacizumab 155Gemcitabine 154Radiotherapy 146camrelizumab 145Fluorouracil 144Cyclophosphamide 123Irinotecan 119Drug Therapy 118sintilimab 107Etoposide 99anlotinib 90S 1 (combination) 88Leucovorin 85pembrolizumab 82Pemetrexed 78Doxorubicin 77toripalimab 76tislelizumab 75Dexamethasone 70Trastuzumab 65Neoadjuvant Therapy 64Rituximab 62Cetuximab 61

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Unknown × Sirolimus × Clear all
NCT05324384 2024-01-24

Different Doses of Sirolimus for the Maintenance Treatment of Kaposiform Hemangioendothelioma

West China Hospital

Phase 2 Unknown
30 enrolled

Kaposiform Hemangioendothelioma, Hemangioendothelioma

NCT00490789 2008-04-30

TESSTAL

Cardiff University

Phase 2 Unknown
14 enrolled

Tuberous Sclerosis, Lymphangioleiomyomatosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡